Silva E G, Tornos C, Malpica A, Mitchell M F
Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
J Cell Biochem Suppl. 1995;23:179-83. doi: 10.1002/jcb.240590924.
Since 1985, when Killackey originally described three cases of endometrial carcinoma in patients receiving tamoxifen, there have been several reports confirming or denying the relationship between tamoxifen and endometrial carcinoma. Our study of 15 patients treated for breast carcinoma with tamoxifen found that papillary serous carcinoma was the most common tumor in this group of patients. Several other retrospective studies reported a high incidence of high-grade endometrioid adenocarcinoma or high-risk variants of endometrial carcinoma in patients receiving tamoxifen.
自1985年基拉克最初描述了3例接受他莫昔芬治疗的患者发生子宫内膜癌的病例以来，已有多篇报告证实或否认他莫昔芬与子宫内膜癌之间的关系。我们对15例接受他莫昔芬治疗乳腺癌的患者进行的研究发现，乳头状浆液性癌是该组患者中最常见的肿瘤。其他几项回顾性研究报告称，接受他莫昔芬治疗的患者中高级别子宫内膜样腺癌或子宫内膜癌高危变体的发生率很高。
